Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Pavan Vaddady"'
Autor:
Yasong Lu, Shuang Liang, Ying Hong, Naoyuki Tajima, Kashyap Patel, Hanbin Li, David R. Wada, Jon Greenberg, Adam Petrich, Hong Zebger‐Gong, Dale Shuster, Pavan Vaddady
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 1, Pp 23-28 (2024)
Abstract To replace the conventional maximum tolerated dose (MTD) approach, a paradigm for dose optimization and dose selection that relies on model‐informed drug development (MIDD) approaches has been proposed in oncology. Here, we report our appl
Externí odkaz:
https://doaj.org/article/07375fb147c347daba609e818c44fe7c
Autor:
Pavan Vaddady, Bhargava Kandala
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1323-1331 (2021)
Abstract ModVizPop is an interactive and dynamic visualization tool developed for simulating differential equation–based population pharmacokinetic (PK) and pharmacodynamic (PD) models with variability. It has a built‐in PK/PD ordinary differenti
Externí odkaz:
https://doaj.org/article/8682781a848847c5a982559e09126690
Autor:
Bhargava Kandala, Pavan Vaddady
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1323-1331 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
ModVizPop is an interactive and dynamic visualization tool developed for simulating differential equation–based population pharmacokinetic (PK) and pharmacodynamic (PD) models with variability. It has a built‐in PK/PD ordinary differential equati
Autor:
Geoffrey A. Walford, Kelly E. Duncan, Moises Hernandez, Pavan Vaddady, Marcus Hompesch, Linda Morrow, S. Aubrey Stoch
Publikováno v:
Clinical pharmacology and therapeutics. 112(1)
Insulin molecules of size much greater than natural insulin have been synthesized and studied with the intention of widening the therapeutic window between adequate glycemic control and hypoglycemia as compared with conventional insulins. MK-1092 is
Autor:
Li Sun, Yang Xu, Neal Dube, Melanie Anderson, Sheila Breidinger, Pavan Vaddady, Bob Thornton, Linda Morrow, Randolph P. Matthews, S. Aubrey Stoch, Eric J. Woolf
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 212
For pharmacokinetics characterization of a therapeutic insulin dimer, an ultrasensitive plasma method was required due to the expected low circulating levels in humans. A bioanalytical strategy combining immunoprecipitation enrichment with liquid chr
Publikováno v:
Antimicrobial Agents and Chemotherapy
Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated
Autor:
Marcus Hompesch, Pavan Vaddady, Geoffrey Walford, Kelly Duncan, Carine Beysen, Linda Morrow, Pranab K. Mitra, Michael Grimm
Publikováno v:
Diabetes. 69
Background: MK-1092, a first-in-class insulin receptor partial agonist, is being developed as a novel basal insulin to treat diabetes. Primary objectives were to assess safety and tolerability of single subcutaneous (SC) doses of MK-1092 in T1DM and
Autor:
Marcus Hompesch, Pranab K. Mitra, Geoffrey Walford, Carine Beysen, Pavan Vaddady, Michael Grimm, Linda Morrow, Kelly Duncan
Publikováno v:
Diabetes. 69
Background: MK-1092, a first-in-class insulin receptor partial agonist, is being developed as a novel basal insulin for patients with T1DM and T2DM. The primary objective of this first-in-human study was to assess safety and tolerability of single su
Publikováno v:
Antimicrobial Agents and Chemotherapy
Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz
Autor:
Patricia Jumes, Lynn Webster, Zifang Guo, Wendy W. Yeh, Luzelena Caro, Pavan Vaddady, Monika Martinho, Dennis Wolford, Deborah Panebianco, Marian Iwamoto, Hwa-Ping Feng, Christina Reitmann, Iain Fraser, Joan R. Butterton, Robert Valesky, William L. Marshall, Fang Liu
Publikováno v:
Clinical and Translational Science. 11:553-561
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK-8742-P010 and MK-5172-P030) in non-hepatitis C virus (HCV)-infected participants on methadone maintenance therap